Suprefact: Uses, Dosage & Side Effects
A GnRH agonist (LHRH analogue) used for the treatment of hormone-dependent prostate cancer by suppressing testosterone production to castrate levels
Suprefact (buserelin) is a synthetic analogue of gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). It belongs to the class of medications called GnRH agonists and is used primarily in the treatment of hormone-dependent prostate cancer. Suprefact works by initially stimulating and then suppressing the production of testosterone, a male sex hormone that can fuel the growth of prostate cancer cells. When administered continuously, Suprefact effectively reduces testosterone levels to castrate levels within 2 to 3 weeks, thereby depriving the tumor of its primary growth stimulus. It is available as a solution for subcutaneous injection and requires a prescription.
Quick Facts: Suprefact
Key Takeaways
- Suprefact (buserelin) is a GnRH agonist that suppresses testosterone production, making it an effective hormonal treatment for advanced prostate cancer as an alternative to surgical castration.
- Treatment initially causes a temporary testosterone surge (tumor flare) that can worsen symptoms; co-administration of an antiandrogen for the first 3–4 weeks is recommended to mitigate this effect.
- The injection is given subcutaneously every 8 hours during the first 7 days, after which the doctor will evaluate testosterone levels and adjust the maintenance regimen accordingly.
- Long-term use can lead to decreased bone density and increased fracture risk; patients should have regular bone density monitoring, especially those with additional risk factors for osteoporosis.
- Suprefact may increase the risk of cardiovascular events, QT prolongation, diabetes complications, and depression; regular monitoring and honest communication with your healthcare team are essential throughout treatment.
What Is Suprefact and What Is It Used For?
Suprefact contains the active substance buserelin, a synthetic peptide analogue of the naturally occurring gonadotropin-releasing hormone (GnRH), which is also referred to as luteinizing hormone-releasing hormone (LHRH). GnRH is a key hormone produced by the hypothalamus in the brain that controls the production of sex hormones. Buserelin belongs to a group of medications known as GnRH agonists or LHRH analogues, which also includes drugs such as leuprorelin (Lupron), goserelin (Zoladex), and triptorelin (Decapeptyl). These medications are widely used in the management of hormone-sensitive cancers and various other conditions.
The primary approved indication for Suprefact injection is the treatment of hormone-dependent (androgen-sensitive) prostate cancer. Prostate cancer is one of the most common cancers in men worldwide, and in the majority of cases, its growth is driven by androgens, particularly testosterone. While the body normally produces testosterone through a carefully regulated hormonal cascade—from hypothalamic GnRH to pituitary luteinizing hormone (LH) to testicular testosterone production—this same pathway can be therapeutically exploited to cut off the tumor's fuel supply.
The mechanism of action of buserelin is both elegant and somewhat counterintuitive. When first administered, buserelin mimics the natural GnRH signal and actually stimulates the pituitary gland to release increased amounts of LH and follicle-stimulating hormone (FSH). This initial stimulation leads to a temporary surge in testosterone levels, which typically peaks during the first week of treatment. This phenomenon is known as the “flare effect” or “tumor flare,” and it is a critically important consideration in patient management because it can temporarily worsen cancer symptoms, particularly in patients with bone metastases.
However, when buserelin is administered continuously rather than in the natural pulsatile pattern, it overwhelms and desensitizes the GnRH receptors on the pituitary gland. This desensitization leads to a dramatic downregulation of LH and FSH secretion. Without LH to stimulate the testes, testosterone production drops to very low levels—comparable to those achieved by surgical castration (orchiectomy). This state, known as “medical castration” or “chemical castration,” is typically achieved within 2 to 3 weeks of continuous treatment. By depriving the prostate cancer cells of testosterone, the primary growth signal is removed, which slows or stops tumor progression in the majority of patients.
The concept of androgen deprivation therapy (ADT) for prostate cancer was first demonstrated by Charles Huggins in the 1940s, work for which he received the Nobel Prize in Physiology or Medicine in 1966. While surgical castration was the original approach, the development of GnRH agonists like buserelin in the 1980s provided a reversible, non-surgical alternative that has become the cornerstone of hormonal therapy for advanced prostate cancer. Today, GnRH agonists remain one of the most widely prescribed classes of drugs for this indication, either as monotherapy or in combination with other treatments such as antiandrogens, chemotherapy, or newer androgen receptor-targeting agents.
Suprefact offers an alternative to surgical castration (orchiectomy) for suppressing testosterone. Both approaches achieve similar testosterone suppression levels. Medical castration with GnRH agonists is reversible in principle—testosterone levels may recover after discontinuation—while surgical castration is permanent. The choice between medical and surgical castration depends on patient preference, clinical circumstances, and cost considerations. Guidelines from the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) recognize both approaches as standard options for androgen deprivation.
What Should You Know Before Using Suprefact?
Contraindications
Suprefact must not be used in patients with a known hypersensitivity (allergy) to buserelin, any other LHRH analogue (such as leuprorelin, goserelin, or triptorelin), or any of the excipients in the formulation. Allergic reactions can range from mild skin reactions to severe anaphylactic shock, although the latter is rare. If you have previously experienced an allergic reaction to any GnRH agonist, you should inform your doctor before starting Suprefact, as cross-reactivity between agents in this drug class is possible.
Suprefact injection is indicated for use in men with prostate cancer and should not be used in women. The product is not intended for use in children or adolescents, as safety and efficacy data in pediatric populations are lacking for this formulation.
Warnings and Precautions
At the start of treatment, Suprefact causes a temporary increase in testosterone levels that can activate the tumor and worsen symptoms. Patients with metastatic disease may experience increased bone pain, muscle weakness in the legs, urinary obstruction, or fluid retention. To prevent this, your doctor will typically prescribe an antiandrogen medication (such as bicalutamide or flutamide) starting approximately 5 days before Suprefact and continuing for the first 3–4 weeks of treatment.
Before and during treatment with Suprefact, inform your doctor about all of the following conditions:
- Metastatic disease: If your cancer has spread (metastases), particularly to the bones or spine, the initial tumor flare can cause serious complications including spinal cord compression and urinary tract obstruction. Close monitoring during the first weeks of treatment is essential.
- Cardiovascular disease: GnRH agonists, including buserelin, have been associated with an increased risk of cardiovascular events such as heart attack and stroke. If you have existing heart disease, high blood pressure, or risk factors for cardiovascular disease, your doctor should carefully weigh the benefits against the risks. Regular blood pressure monitoring is recommended, as Suprefact can affect blood pressure.
- QT prolongation: Suprefact may affect the electrical activity of the heart (QT prolongation), which can lead to potentially dangerous heart rhythm disturbances. This risk is heightened when used with other QT-prolonging medications such as amiodarone, sotalol, quinidine, procainamide, methadone, moxifloxacin, or certain antipsychotic drugs. Your doctor may monitor your heart rhythm with an electrocardiogram (ECG).
- Diabetes: Suprefact can affect glucose metabolism and alter blood sugar levels. If you have diabetes, monitor your blood glucose levels more frequently during treatment. Your diabetes medications may need adjustment.
- Depression and mental health: Depression, including severe depression, has been reported in patients taking GnRH agonists. If you have a history of depression or are experiencing mood changes, emotional instability, or anxiety, inform your doctor promptly. Be vigilant about your mental wellbeing throughout treatment.
- Bone health: Long-term testosterone suppression with GnRH agonists leads to decreased bone mineral density and increases the risk of osteoporosis and fractures. This risk is compounded if you have additional risk factors such as alcohol misuse, smoking, family history of osteoporosis, or concurrent treatment with anticonvulsants or corticosteroids. Your doctor should assess your bone density at baseline and at regular intervals, and may prescribe calcium, vitamin D supplements, or bisphosphonates as preventive measures.
- Anemia: Suprefact may increase the risk of anemia (low red blood cell count). Report symptoms such as unusual tiredness, shortness of breath, or rapid heartbeat to your doctor.
Pregnancy and Breastfeeding
Suprefact injection is indicated for use in men only and is not intended for use in women. The drug suppresses gonadal hormone production and would have significant effects on reproductive function and fetal development. Women of childbearing potential who may be partners of men receiving Suprefact should be aware of the drug's effects on male fertility. Testosterone suppression caused by GnRH agonists can impair spermatogenesis, and patients may wish to discuss sperm cryopreservation with their doctor before starting treatment if future fertility is a concern.
Driving and Operating Machinery
Suprefact may cause side effects such as drowsiness, dizziness, and impaired concentration that could affect your ability to drive or operate machinery. You should be aware of how the medication affects you individually before engaging in activities that require alertness and quick reaction times. If you experience any of these effects, refrain from driving or operating machinery and discuss the issue with your doctor.
Important Information About Ingredients
Suprefact injection contains benzyl alcohol (10 mg per mL). Benzyl alcohol may cause allergic reactions in some individuals. If you have impaired liver or kidney function, consult your doctor or pharmacist before using this medication, as large amounts of benzyl alcohol can accumulate in the body and cause metabolic acidosis.
This medication contains less than 1 mmol (23 mg) sodium per mL, meaning it is essentially sodium-free and is not expected to contribute meaningfully to dietary sodium intake.
How Does Suprefact Interact with Other Drugs?
Drug interactions with Suprefact primarily relate to its hormonal effects and its potential to affect cardiac electrical conduction. Because testosterone suppression affects multiple body systems including metabolism, cardiovascular function, and bone homeostasis, the interplay with other medications can be clinically significant. It is essential that your doctor has a complete and up-to-date list of all medications you are taking, including prescription drugs, over-the-counter products, and herbal supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| QT-prolonging antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) | Additive QT prolongation; increased risk of serious cardiac arrhythmias including torsades de pointes | Monitor ECG closely; avoid combination if possible |
| Methadone | Additive QT prolongation risk | ECG monitoring recommended; assess risk-benefit |
| Moxifloxacin (fluoroquinolone antibiotic) | Additive QT prolongation risk | Consider alternative antibiotic if possible |
| Antipsychotics (haloperidol, pimozide, quetiapine) | Additive QT prolongation risk; potential for cardiac arrhythmias | ECG monitoring recommended; dose adjustments may be needed |
| Diabetes medications (insulin, metformin, sulfonylureas) | Suprefact may impair glucose tolerance and reduce effectiveness of diabetes medications | Monitor blood glucose frequently; adjust diabetes medication doses as needed |
Minor Interactions
While the interactions listed above are the most clinically significant, Suprefact's broad hormonal effects mean that subtle interactions with other medications are possible. Testosterone suppression can affect lipid metabolism, body composition, and insulin sensitivity, which may indirectly influence the efficacy or safety profile of other medications. For example, changes in body fat distribution may alter the pharmacokinetics of lipophilic drugs, and metabolic changes may affect the dosing requirements of antihypertensive medications.
Antiandrogens such as bicalutamide, flutamide, and enzalutamide are commonly used alongside Suprefact intentionally, particularly during the initial treatment phase to block the effects of the testosterone flare. This is a planned therapeutic combination, not an adverse interaction. Your doctor will determine the appropriate antiandrogen and its duration based on your clinical situation.
Herbal products and dietary supplements should also be disclosed to your healthcare provider. Some herbal products may have hormonal effects (such as phytoestrogens from soy or red clover) that could theoretically interact with the hormonal manipulation achieved by Suprefact, although clinical evidence for significant interactions is limited.
What Is the Correct Dosage of Suprefact?
Always use Suprefact exactly as your doctor has prescribed. The dosage and schedule are carefully determined to achieve and maintain adequate testosterone suppression while minimizing side effects. Do not change your dose or stop taking Suprefact without consulting your doctor, as this could lead to a rebound in testosterone levels and disease progression.
Adults
Initial Phase (Days 1–7)
The recommended starting dose is 0.5 mL (0.5 mg buserelin) administered as a subcutaneous injection every 8 hours (three times daily). This intensive initial phase is designed to achieve rapid pituitary desensitization. Ideally, this phase should be conducted under hospital supervision, where healthcare professionals can administer the injections and monitor for early signs of tumor flare or other adverse effects.
Maintenance Phase
After the first 7 days, your doctor will take blood samples to measure your testosterone levels. Based on these results, the maintenance dose will be determined. The goal is to maintain testosterone at castrate levels (typically below 50 ng/dL or 1.7 nmol/L). Testosterone levels are monitored at regular intervals to ensure continued suppression, and dose adjustments are made as needed.
Suprefact injection is given subcutaneously (under the skin), typically in the abdomen, thigh, or upper arm. It is important to rotate injection sites to minimize local skin reactions. Your healthcare team will provide training on proper injection technique if you will be administering the injections yourself at home after the initial hospital phase.
For the treatment to be effective, strict adherence to the prescribed injection schedule is essential. Missing doses or administering them at irregular intervals can lead to suboptimal testosterone suppression and potentially allow disease progression. Set reminders or use a dosing diary to help maintain consistency.
Children
Suprefact injection is not indicated for use in children or adolescents. There are insufficient safety and efficacy data to support the use of this formulation in the pediatric population. If buserelin is required for a pediatric indication (which would be determined by a specialist), alternative formulations and dosing regimens may apply under strict specialist supervision.
Elderly
Since prostate cancer predominantly affects older men, many patients receiving Suprefact are elderly. No specific dose adjustment is required based on age alone. However, elderly patients are more likely to have comorbidities such as cardiovascular disease, diabetes, osteoporosis, and renal or hepatic impairment that may influence the risk-benefit profile of treatment. Closer monitoring of bone density, cardiovascular health, and metabolic parameters is generally recommended in older patients.
Missed Dose
If you miss a dose, administer it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not double the dose to make up for a missed injection. If you have missed multiple doses or are unsure how to proceed, contact your doctor or pharmacist for guidance. Consistent dosing is crucial for maintaining adequate testosterone suppression.
Overdose
If you accidentally inject too much Suprefact, or if someone else inadvertently receives the medication, contact your doctor, hospital, or poison control center immediately. Symptoms of overdose may include weakness, anxiety, dizziness, nausea, headache, hot flashes, abdominal pain, swelling (edema) of the ankles and lower legs, breast tenderness, and reactions at the injection site. Treatment is generally supportive, as there is no specific antidote for buserelin overdose. Medical professionals will monitor vital signs and provide symptomatic care as needed.
What Are the Side Effects of Suprefact?
Like all medications, Suprefact can cause side effects, although not everyone who takes it will experience them. Many side effects of Suprefact are directly related to the suppression of testosterone, which affects numerous body systems beyond the prostate. Understanding potential side effects helps you recognize important symptoms early and communicate effectively with your healthcare team.
Contact your doctor or seek emergency care immediately if you experience symptoms such as rash, difficulty swallowing or breathing, or swelling of the lips, face, throat, or tongue. These may be signs of a serious allergic reaction (anaphylaxis), which is rare but potentially life-threatening. Also seek urgent medical help if you experience severe bone pain, leg weakness, or urinary retention during the first weeks of treatment, as these may indicate tumor flare.
Common
- Headache
- Hot flashes (flushing), sweating
- Pain, redness, or swelling at injection site
- Erectile dysfunction (impotence)
- Decreased testicle size
- Decreased libido (sex drive)
- Mood changes, depression (with long-term use)
Uncommon
- Changes in liver function test values
- Weight loss or weight gain
- Drowsiness, dizziness
- Constipation
- Allergic skin reactions (redness, itching, hives)
- Breast enlargement (gynecomastia, non-painful)
- Mood changes, depression (with short-term use)
- Fluid retention (edema) in ankles and legs
- Fatigue
Rare
- Changes in blood lipid levels
- Palpitations
- Sleep disturbances, memory and concentration problems
- Nausea, vomiting, diarrhea
- Increased or decreased body or scalp hair
- Worsening of high blood pressure
- Emotional instability, anxiety
- Elevated bilirubin levels
- Severe allergic reactions (anaphylaxis)
Very Rare
- Changes in blood cell counts
- Musculoskeletal discomfort and pain
- Visual disturbances (e.g., blurred vision), pressure behind the eyes
- Tinnitus, hearing disturbances
- Decreased bone mineral density, increased fracture risk
- Increased thirst, appetite changes, decreased glucose tolerance
- Growth of benign pituitary tumor
- Mild transient tumor-related pain
- General deterioration in wellbeing
Frequency Not Known
- QT prolongation (changes visible on ECG)
- Abnormal skin sensations such as tingling or numbness (paresthesia)
It is important to understand that many of the side effects listed above are a direct consequence of testosterone suppression rather than a toxic effect of the drug itself. Hot flashes, reduced libido, erectile dysfunction, and mood changes are experienced by the majority of men undergoing any form of androgen deprivation therapy, whether medical or surgical. Lifestyle modifications such as regular exercise, a healthy diet, psychological support, and adequate sleep can help mitigate some of these effects.
The risk of cardiovascular events (heart attack, stroke) and metabolic syndrome (diabetes, obesity, dyslipidemia) is increased with long-term androgen deprivation therapy. The European Association of Urology (EAU) guidelines recommend cardiovascular risk assessment before starting ADT and regular metabolic monitoring throughout treatment. Patients should be encouraged to maintain an active lifestyle and a balanced diet to counteract these metabolic effects.
If you experience any side effects, including those not listed here, report them to your healthcare provider. Reporting side effects helps regulatory authorities continuously monitor the benefit-risk balance of medications and may contribute to improved safety information for future patients.
How Should You Store Suprefact?
Proper storage of Suprefact is essential to maintain the medication's effectiveness and safety. Store the vials at room temperature, not exceeding 25°C (77°F). Do not freeze the solution. Keep the vials in their original packaging to protect them from light until you are ready to use them.
Always keep Suprefact out of the sight and reach of children. Accidental exposure to GnRH agonists can have significant hormonal effects, especially in children, and medical attention should be sought immediately if accidental exposure occurs.
Check the expiry date printed on the vial and outer packaging before each use. The expiry date refers to the last day of the stated month. Do not use Suprefact after this date, as the chemical stability and sterility of the product cannot be guaranteed beyond the manufacturer's specified shelf life.
After opening a multi-dose vial, follow your pharmacist's or doctor's instructions regarding the in-use shelf life. In general, injectable solutions should be used promptly after opening, and any remaining solution should be discarded according to local disposal guidelines. Do not dispose of medications in wastewater or household waste. Return unused or expired medications to a pharmacy for safe disposal to protect the environment.
What Does Suprefact Contain?
Understanding the composition of your medication can help you identify potential allergens and understand its formulation. Suprefact solution for injection contains the following components:
| Component | Role | Details |
|---|---|---|
| Buserelin acetate | Active ingredient | Equivalent to 1 mg buserelin per mL |
| Benzyl alcohol | Preservative | 10 mg per mL; may cause allergic reactions |
| Sodium hydroxide | pH adjuster | Maintains solution stability |
| Sodium dihydrogen phosphate | Buffer | Maintains pH of solution |
| Sodium chloride | Tonicity agent | Ensures isotonicity for injection |
| Water for injections | Solvent | Pharmaceutical-grade water |
Suprefact is supplied as a clear, colorless solution for injection. It comes in transparent glass vials with a dark grey rubber stopper, aluminum cap, and plastic flip-off top. Each pack contains 2 vials of 5.5 mL each. Inspect the solution before each use—do not use if it appears cloudy, discolored, or contains particles.
The marketing authorization holder is CHEPLAPHARM Arzneimittel GmbH (Greifswald, Germany), and the product is manufactured by Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, Germany) and Laboratorios Farmalan S.A. (León, Spain).
Frequently Asked Questions About Suprefact
Suprefact (buserelin) is a GnRH agonist used primarily for the treatment of hormone-dependent prostate cancer. It works by suppressing testosterone production to castrate levels, which slows or stops the growth of prostate cancer cells that depend on testosterone to proliferate. In some countries, buserelin formulations are also used in fertility treatments and for endometriosis, though the Suprefact injection formulation is specifically indicated for prostate cancer.
Suprefact works by mimicking the natural hormone GnRH (gonadotropin-releasing hormone). When given continuously, it initially causes a brief surge in testosterone (tumor flare), but then overwhelms and desensitizes the GnRH receptors in the pituitary gland. This leads to a dramatic drop in LH and FSH production, which in turn reduces testosterone to castrate levels within 2–3 weeks. Since prostate cancer growth is often driven by testosterone, this chemical castration effectively slows tumor progression.
Tumor flare is a temporary worsening of symptoms that can occur during the first 1–3 weeks of Suprefact treatment. Because buserelin initially stimulates testosterone production before suppressing it, patients with metastatic prostate cancer may experience increased bone pain, urinary obstruction, muscle weakness in the legs, or fluid retention. To prevent tumor flare, doctors typically prescribe an antiandrogen medication (such as bicalutamide or flutamide) starting about 5 days before Suprefact and continuing for the first 3–4 weeks of treatment.
Yes, Suprefact can cause decreased bone mineral density (osteoporosis) and increase the risk of fractures, particularly with long-term use. This is a well-known consequence of testosterone suppression. Patients with additional risk factors for osteoporosis—such as alcohol misuse, smoking, family history of osteoporosis, or concurrent use of anticonvulsants or corticosteroids—are at greater risk. Doctors should monitor bone density regularly and may prescribe calcium, vitamin D supplements, or bone-protective medications to reduce this risk.
The duration of Suprefact treatment depends on the type and stage of prostate cancer, response to treatment, and overall treatment plan. For advanced prostate cancer, androgen deprivation therapy is often continued indefinitely (continuous ADT) or may be given intermittently with planned treatment breaks (intermittent ADT). Some patients receive Suprefact for months, while others may use it for years. Your oncologist or urologist will determine the optimal treatment duration based on your individual clinical situation, PSA levels, and disease status.
Alternatives to Suprefact for androgen deprivation include other GnRH agonists (leuprorelin, goserelin, triptorelin), GnRH antagonists (degarelix, relugolix), and surgical castration (bilateral orchiectomy). GnRH antagonists achieve testosterone suppression without the initial flare effect seen with GnRH agonists. Your doctor will recommend the most appropriate option based on your disease stage, risk profile, and preferences. In some cases, ADT is combined with newer agents such as abiraterone, enzalutamide, or docetaxel for enhanced efficacy.
References
- European Medicines Agency (EMA). Suprefact – Summary of Product Characteristics (SmPC). Updated 2025. Available at: www.ema.europa.eu
- European Association of Urology (EAU). EAU Guidelines on Prostate Cancer. 2024 Edition. Available at: uroweb.org/guidelines/prostate-cancer
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- Huggins C, Hodges CV. Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Research. 1941;1(4):293–297.
- Cornford P, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Urology. 2024;85(2):157–190.
- Levine GN, et al. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association. Circulation. 2010;121(6):833–840.
- Saad F, et al. Bone Health in Men with Prostate Cancer on Long-term Androgen Deprivation Therapy: A Comprehensive Review. European Urology. 2019;75(6):979–989.
- British National Formulary (BNF). Buserelin. National Institute for Health and Care Excellence (NICE). Updated 2025.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising specialists in oncology, urology, and clinical pharmacology.
Medical Content Team
Our medical writers hold advanced degrees in medicine and pharmacology, with clinical experience in oncology and urology. All content is evidence-based and aligned with current international guidelines.
Medical Review Board
All articles undergo rigorous peer review by our independent Medical Review Board, ensuring accuracy, completeness, and adherence to the GRADE evidence framework and international treatment guidelines.